ethyl 3-(cyclopropylamino)-2-[(2-fluoro-5-iodophenyl)-carbonyl]-2-propenoate | 1253591-44-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-(cyclopropylamino)-2-[(2-fluoro-5-iodophenyl)-carbonyl]-2-propenoate
• 英文别名: ethyl 3-(cyclopropylamino)-2-[(2-fluoro-5-iodophenyl)carbonyl]-2-propenoate
• CAS: 1253591-44-4
• 化学式: C₁₅H₁₅FINO₃
• 分子量: 403.192
• InChiKey: WEYINGZJCYVATR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.81
• 重原子数：
  21.0
• 可旋转键数：
  6.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  ethyl 3-(cyclopropylamino)-2-[(2-fluoro-5-iodophenyl)-carbonyl]-2-propenoate 在 potassium carbonate 、 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 1-cyclopropyl-1,4-dihydro-6-iodo-4-oxo-3-quinolinecarboxamide-N-methyl
  参考文献：
  名称：

  一种红霉素衍生物及其制备方法

  摘要：

  本发明提供一种红霉素衍生物，其特征在于，所述红霉素衍生物包括具有通式Ⅰ的化合物，或者，所述红霉素衍生物包括所述通式Ⅰ的化合物与无机酸或有机酸形成的药学可接受的盐，所述红霉素衍生物既能够较好的适应工业化生产，并且针对临床上常见的红霉素耐药的肺炎链球菌、金黄色葡萄球菌、化脓链球菌、卡他莫拉和嗜血流感菌等致病菌具有良好的抗敏感菌和抗耐药菌活性，能有效治疗临床细菌性肺炎或者其他微生物(如支原体、军团菌属等)引起的肺炎、以及其他组织感染；

  公开号：

  CN109942653B
• 作为产物：
  描述：

  2-氟-5-碘代苯甲酰氯 在 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 生成 ethyl 3-(cyclopropylamino)-2-[(2-fluoro-5-iodophenyl)-carbonyl]-2-propenoate
  参考文献：
  名称：

  一种大环内酯和喹诺酮杂合物及其制备方法

  摘要：

  本发明提供一种大环内酯和喹诺酮杂合物，其特征在于，所述大环内酯和喹诺酮杂合物包括具有通式I和通式Ⅱ的化合物，或者，所述大环内酯和喹诺酮杂合物包括所述通式I和通式Ⅱ的化合物与无机酸或有机酸形成的药学可接受的盐，所述大环内酯和喹诺酮杂合物既能够较好的适应工业化生产，并且针对临床上常见的红霉素耐药的肺炎链球菌、金黄色葡萄球菌、化脓链球菌、卡他莫拉和嗜血流感菌等致病菌具有良好的抗敏感菌和抗耐药菌活性，能有效治疗临床细菌性肺炎或者其他微生物(如支原体、军团菌属等)引起的肺炎、以及其他组织感染；

  公开号：

  CN109942654B

文献信息

• 4-Quinolone-3-carboxylic acids as cell-permeable inhibitors of protein tyrosine phosphatase 1B
  作者：Ying Zhi、Li-Xin Gao、Yi Jin、Chun-Lan Tang、Jing-Ya Li、Jia Li、Ya-Qiu Long

  DOI：10.1016/j.bmc.2014.05.028

  日期：2014.7

  Protein tyrosine phosphatase 1B is a negative regulator in the insulin and leptin signaling pathways, and has emerged as an attractive target for the treatment of type 2 diabetes and obesity. However, the essential pharmacophore of charged phosphotyrosine or its mimetic confer low selectivity and poor cell permeability. Starting from our previously reported aryl diketoacid-based PTP1B inhibitors, a drug-like scaffold of 4-quinolone-3-carboxylic acid was introduced for the first time as a novel surrogate of phosphotyrosine. An optimal combination of hydrophobic groups installed at C-6, N-1 and C-3 positions of the quinolone motif afforded potent PTP1B inhibitors with low micromolar IC50 values. These 4-quinolone-3-carboxylate based PTP1B inhibitors displayed a 2-10 fold selectivity over a panel of PTP's. Furthermore, the bidentate inhibitors of 4-quinolone-3-carboxylic acids conjugated with aryl diketoacid or salicylic acid were cell permeable and enhanced insulin signaling in CHO/hIR cells. The kinetic studies and molecular modeling suggest that the 4-quinolone-3-carboxylates act as competitive inhibitors by binding to the PTP1B active site in the WPD loop closed conformation. Taken together, our study shows that the 4-quinolone-3-carboxylic acid derivatives exhibit improved pharmacological properties over previously described PTB1B inhibitors and warrant further preclinical studies.
• Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens
  作者：Cong-Xuan Ma、Wei Lv、Ya-Xin Li、Bing-Zhi Fan、Xu Han、Fan-Sheng Kong、Jing-Chao Tian、Mark Cushman、Jian-Hua Liang

  DOI：10.1016/j.ejmech.2019.02.073

  日期：2019.5

  Constitutively erythromycin-resistant apathogens are more difficult to address than inducibly resistant and efflux-resistant strains. Three series of the 4th generation 2-fluoro 9-oxime erythromycin ketolides were synthesized and evaluated. Incorporation of substituted heteroaryl groups (a - m), in contrast to previously reported the unsubstituted heteroaryl groups, proved to the beneficial for enhancement of the activities of the 9-propgargyl ketolide 8 series and the 9-allyl ketolide 14 series. But these aryl groups (a - m) cannot supply the resulting compounds 8 and 14, unlike corresponding the 6-allyl ketolide 20 series, with activity against constitutively resistant Streptococcus pneumoniae. However, hybrids of macrolides and quinolones (8, 14 and 20, Ar = n - t) exhibited not only high activities against susceptible, inducibly erm-mediated resistant, and efflux-mediated resistant strains, but also significantly improved potencies against constitutively resistant Streptococcus pneumoniae and Streptococcus pyogenes. The capacity was highlighted by introduction of newly designed carbamoyl quinolones (q, r, s and t) rather than commonly seen carboxy quinolones (o and p) as the pharmacophores. Structure-activity relationships and molecular modelling indicated that 8r, 14r and 20q may have different binding sites compared to current erythromycins. Moreover, 8r, 14r and 20q have 2.5-3.6 times prolonged half-life and 2.3- to 2.6-fold longer mean residence time in vivo over telithromycin. These findings pave the way for rational design of novel non-telithromycin macrolides that target new binding sites within bacterial ribosomes. (C) 2019 Elsevier Masson SAS. All rights reserved.
• Synthesis and biological activity of 4″-O-acyl derivatives of 14- and 15-membered macrolides linked to ω-quinolone-carboxylic unit
  作者：Maja Matanović Škugor、Vlado Štimac、Ivana Palej、Đurdjica Lugarić、Hana Čipčić Paljetak、Darko Filić、Marina Modrić、Ivica Đilović、Dubravka Gembarovski、Stjepan Mutak、Vesna Eraković Haber、David J. Holmes、Zrinka Ivezić-Schoenfeld、Sulejman Alihodžić

  DOI：10.1016/j.bmc.2010.06.050

  日期：2010.9

  The synthesis and antimicrobial activity of a new class of macrolide antibiotics which consist of a macrolide scaffold and a quinolone unit covalently connected by an appropriate linker are described. Optimization of several synthetic steps and structural properties of lead compound 26 are discussed. Promising antibacterial properties of this compound and some of its analogues are reported. (C) 2010 Elsevier Ltd. All rights reserved.